High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU Study

NCT ID: NCT03342625

Last Updated: 2025-10-02

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-06-07
• Study Completion Date: 2027-01-31

Brief Summary

Monocentric prospective study evaluating the efficacy of High intensity focused ultrasound (HIFU) in breast tumors.

Detailed Description

Incidence of breast cancer increases with the lifetime of the population, and represents an important socio-economic issue. Diagnosis and treatment are major public health issues. High Instensity Focused Ultrasound (HIFU) is a minimally invasive technique which decreases the risk of post-treatment complications and allows shorter hospitalization times. This technology is also remarkable for the absence of limitation related to the dose delivered, which makes it possible to repeat if necessary and the absence of ionizing radiation both for the treatment itself and for its guidance (MRI).

The main objective is to evaluate the efficacy of HIFU for the treatment of breast tumors, based on histological criteria.

Indication :

Histologically invasive ductal carcinoma, T0, with unifocal or plurifocal lesion, with or without associated microcalcifications, measuring 15 mm maximum on ultrasound and clinical N0.

Course of the study :

• Signature of consent,
• Clinical and radiological assessment at Baseline,
• Realization of the HIFU procedure under local anesthesia and sedation (J0),
• Total or partial mastectomy depending on the lesion (between D2 and D8),
• Consultation with surgeon (J30),

Number of patients :

15 patients will be included in this pilot study. If no success is observed, the study will be stopped and the technique considered inefficient. If there are one or more successes, an Independant Data Monitoring Committee (IDMC) will meet to propose an additional trial if necessary with the data from this trial.

Conditions

Breast Cancer Female

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

High Intensity Focused Ultrasound

High Intensity Focused Ultrasound for the treatment of breast tumors, guided by MRI

Group Type: EXPERIMENTAL

High Instensity Focused Ultrasound

Intervention Type: DEVICE

High Intensity Focused Ultrasound guided by MRI

Interventions

High Instensity Focused Ultrasound

High Intensity Focused Ultrasound guided by MRI

Intervention Type: DEVICE

Other Intervention Names

HIFU

Eligibility Criteria

Inclusion Criteria

1. Histologically proven infiltrating ductal carcinoma with the analysis of hormone receptors, tumor grade, Her-2 expression.

2. T0 lesion, unifocal or plurifocal, with or without micro-calcifications associated, measuring 15 mm maximum major axis on ultrasound.

3. Clinical N0.

4. Bra cup size greater than or equal to B.

5. Markable and identifiable lesion in MRI.

6. Indication of partial or total mastectomy in case of multifocal lesions or extensive calcification associated with axillary surgery.

7. Breast assessment performed by a referent radiologist: Mammography, ultrasound, clinical examination.

8. No contraindication to MRI.

Exclusion Criteria

1. Infiltrating lobular carcinoma and Pure ductal carcinoma in situ.

2. Bilateral lesion.

3. Non-detectable MRI lesions, within 10 mm of the skin, greater than 15 mm on ultrasound.

4. Unifocal palpable tumor.

5. Cup size bra equal to A.

6. Cutaneous lesion on the breast to be treated by HIFU.

7. Impossibility of ventral decubitus immobility, extended arm, during 1 hour.

8. Pregnant or postpartum patient.

9. Patient participating in another interventional clinical trial within 30 days of enrollment and during the trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Ligue contre le cancer, France

OTHER

Sponsor Role: collaborator

Institut Bergonié

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Jean PALUSSIERE, MD

Role: STUDY_CHAIR

Institut Bergonié

Locations

Institut Bergonie

Bordeaux, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Jean PALUSSIERE, MD

Role: CONTACT

j.palussiere@bordeaux.unicancer.fr

+33 5 56 33 37 50

Simone MATHOULIN-PELISSIER, MD, PhD

Role: CONTACT

s.mathoulin@bordeaux.unicancer.fr

Facility Contacts

Jean PALUSSIERE, MD

Role: primary

j.palussiere@bordeaux.unicancer.fr

+33 5 56 33 37 50

Christine TUNON DE LARA, MD

Role: backup

c.tunondelara@bordeaux.unicancer.fr

+33 5 56 33 33 35

Other Identifiers

ID-RCB number : 2017-A01490-53

Identifier Type: OTHER

Identifier Source: secondary_id

IB 2015-01

Identifier Type: -

Identifier Source: org_study_id